AGA临床实践更新:非壶腹部十二指肠病变专家综述
该AGA临床实践更新专家综述针对非壶腹部十二指肠息肉(占上消化道内镜5%,腺瘤占10%-20%)的评估、风险分层、内镜切除与监测及并发症管理提出13条最佳实践建议。建议所有散发性十二指肠腺瘤考虑内镜切除(较手术并发症少、资源消耗低),但需结合患者合并症与预期寿命;平坦非 bulky 病变<20 mm可用冷圈套切除,>20 mm或Paris Is型大组件用传统热圈套EMR,切缘热消融可降低复发至<2%-5%。术后出血多发生于48小时内、风险与病变大小成比例(>3 cm者>25%),穿孔需术中识别。完全切除后首次监测间隔6个月,家族性腺瘤性息肉病相关腺瘤按大小≥1 cm、形态、高级别异型增生和/或Spiegelman标准考虑切除。
要点
- 所有散发性十二指肠腺瘤应考虑内镜切除,但需将患者合并症与预期寿命纳入决策(建议7)。
- 平坦非 bulky 十二指肠腺瘤<20 mm,冷圈套切除可考虑用于有合并症患者,有效且复发风险极低;>20 mm或Paris Is型大组件用传统热圈套EMR,切缘热消融可考虑使复发风险降至<2%-5%(建议8、9)。
- 术后出血通常发生于术后48小时内、风险与病变大小成比例;>3 cm病变出血风险>25%,可能危及生命并伴血流动力学障碍,复苏后内镜止血通常有效(建议10)。
- 完全切除十二指肠腺瘤后首次内镜监测间隔为6个月;复发常伴瘢痕、不宜常规圈套切除,可能需撕脱技术(建议12)。
- 发现十二指肠腺瘤时,若近3年内未行高质量结肠镜检查,应行结肠镜检查(建议4)。
适用人群与场景
- 非壶腹部十二指肠息肉患者:多数为无症状患者偶然发现,腺瘤估计占10%-20%。
- 散发性与非散发性十二指肠腺瘤患者(建议5、7涉及)。
- 家族性腺瘤性息肉病相关的非壶腹部十二指肠腺瘤患者(建议13)。
- Peutz-Jeghers综合征患者可受益于胶囊内镜定期小肠检查(建议5)。
诊断标准与关键阈值
- 十二指肠腺瘤内镜切除决策需结合患者合并症与预期寿命(建议7)。
- 平坦非bulky病变<20 mm:冷圈套切除有效且复发风险极低,有合并症患者可考虑(建议8)。
- 病变>20 mm或含大Paris Is型组件:应行传统热圈套EMR(建议9)。
- 家族性腺瘤性息肉病相关非壶腹部十二指肠腺瘤:基于大小≥1 cm、形态学特征、晚期组织学(即高级别异型增生)和/或Spiegelman标准考虑内镜切除(建议13)。
- 完全切除后首次内镜监测间隔6个月(建议12)。
处置流程与药物剂量
- 非肿瘤性十二指肠病变(如化生性小凹上皮和胃异位)无需内镜切除,除非有症状或出血(建议1)。
- 理想十二指肠内镜检查包括识别大乳头和小乳头并拍照记录以确保病变未累及;前视胃镜加透明远端附件装置改善乳头和内侧壁可视化;胃镜无法见大、小乳头时及距壶腹部5 cm内大部分内侧壁病变应使用侧视十二指肠镜(建议2)。
- 所有十二指肠息肉应按大小、Paris形态、疑似组织学起源层(黏膜或上皮下病变)、十二指肠位置(D1-4)和方位(前、后、内、外侧壁)及与大乳头的邻近/关系描述(建议3)。
- 内镜十二指肠切除方式(热vs冷、传统vs水下EMR)应个体化以降低出血风险,基于病变大小、形态、患者合并症和内镜医师技术熟练度(建议8)。
- >20 mm或含大Paris Is型组件应行传统热圈套EMR;EMR后切缘热消融可考虑以降低复发风险至<2%-5%(建议9)。
- 息肉切除/EMR缺损评估至关重要,以识别术后十二指肠穿孔;未识别未处理可能危及生命且常需手术(建议11)。
- 完全切除后6个月首次内镜监测;复发常伴瘢痕、不宜常规圈套切除,可能需撕脱技术治愈(建议12)。
红旗征与不能漏的情况
- 术后出血通常发生于术后48小时内,风险与病变大小成比例;>3 cm病变出血风险>25%,可能危及生命并伴血流动力学障碍,复苏后内镜止血通常有效(建议10)。
- 息肉切除/EMR缺损需评估以识别术后十二指肠穿孔,未识别未处理可能危及生命且常需手术(建议11)。
研究设计与关键结果
- 非壶腹部十二指肠息肉见于高达5%的上消化道内镜,绝大多数为无症状患者偶然发现;腺瘤估计占10%-20%。
- 国际指南大多推荐所有十二指肠腺瘤应考虑内镜切除;前瞻性研究中这与近15%的不良事件率相关(主要为出血和穿孔),监测中有显著局部复发。
- 内镜切除与手术相比, definitive 治疗十二指肠腺瘤并发症少、资源消耗低且费用低,因此是首选治疗选择(建议6)。
- 与结肠腺瘤相比,十二指肠腺瘤恶变时间过程可能更漫长,而切除相关并发症风险大得多(建议7)。
- 平坦十二指肠腺瘤冷圈套切除可降低术后出血风险,<20 mm病变有效且复发风险极低(建议8)。
证据类型、等级与局限
- 证据类型:专家综述(AGA临床实践更新专家综述),基于已发表文献回顾和专家意见,未进行系统评价。
- 这些最佳实践建议不带有关于证据质量或推荐强度的正式评级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 发现十二指肠腺瘤时,若近3年内未行高质量结肠镜检查,应行结肠镜检查(建议4)。
- 散发性与非散发性十二指肠腺瘤患者不推荐常规小肠检查(即胶囊内镜);Peutz-Jeghers综合征患者胶囊内镜定期小肠检查可能有益(建议5)。
- 所有散发性十二指肠腺瘤因恶变风险应考虑内镜切除,但合并症和预期寿命须仔细纳入决策(建议7)。
- 有合并症的平坦非bulky病变<20 mm患者,可考虑冷圈套切除(建议8)。
- >20 mm或含大Paris Is型组件的十二指肠腺瘤应行传统热圈套EMR,切缘热消融可考虑以降低复发至<2%-5%(建议9)。
指南或共识出处
- 美国胃肠病学会(AGA)临床实践更新专家综述:非壶腹部十二指肠病变(AGA Clinical Practice Update on Nonampullary Duodenal Lesions: Expert Review),发表于Gastroenterology。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
DESCRIPTION: Nonampullary duodenal polyps are found in up to 5% of all upper endoscopies; the vast majority are identified incidentally in asymptomatic patients. Although most are benign, adenomas are estimated to account for 10%-20% of these lesions. Most international guidelines recommend that all duodenal adenomas should be considered for endoscopic resection; this may be associated with a near 15% adverse event rate (predominantly bleeding and perforation) in prospective studies, with substantial local recurrence on surveillance. The aim of this American Gastroenterological Association (AGA) Clinical Practice Update Expert Review was to describe how individuals should be evaluated and risk-stratified for duodenal polyps, the best approaches to endoscopic resection and surveillance, and management of complications, highlighting opportunities for future research to fill gaps in the existing literature.
METHODS: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Non-neoplastic duodenal lesions (eg, metaplastic foveolar epithelium and gastric heterotopia) may mimic neoplastic adenomatous pathology. Careful optical evaluation and pathologic correlation may be necessary to exclude dysplasia. Nondysplastic lesions do not require endoscopic resection unless they are symptomatic or bleeding. BEST PRACTICE ADVICE 2: Ideal duodenal endoscopic inspection includes identification of the major and minor papilla with photodocumentation to ensure no involvement by the lesion. Adding a clear distal attachment device to a forward-viewing gastroscope improves visualization of the papilla and the medial wall. A side-viewing duodenoscope should be used when the major and minor papilla are not visible with the gastroscope and for most lesions on the medial wall of the duodenum within 5 cm of the ampulla. BEST PRACTICE ADVICE 3: All duodenal polyps should be described according to their size, Paris morphology, suspected histologic layer of origin (mucosal lesion or subepithelial lesion), duodenal location (D1-4) and orientation (anterior, posterior, medial, or lateral wall), and proximity/relationship to the major papilla to facilitate therapeutic planning and subsequent surveillance. BEST PRACTICE ADVICE 4: Given the high frequency of concomitant colonic adenomas in patients with duodenal adenomas, on identification of a duodenal adenoma, a colonoscopy should be performed if a high-quality examination has not been performed in the last 3 years. BEST PRACTICE ADVICE 5: Routine small bowel investigation (ie, capsule endoscopy) is not advised in patients with sporadic and nonsporadic duodenal adenomas. Periodic small bowel inspection with capsule endoscopy may be of benefit in patients with Peutz-Jeghers syndrome. BEST PRACTICE ADVICE 6: Definitive treatment of duodenal adenomas by endoscopic resection is less morbid, resource-intensive, and expensive than surgery and is therefore the preferred treatment option. BEST PRACTICE ADVICE 7: Due to the risk of malignant transformation, all sporadic duodenal adenomas should be considered for endoscopic resection. However, in comparison with colonic adenomas, the time course to malignant transformation may be more prolonged, and the risk of resection-related morbidity much greater. Therefore, the comorbidities and anticipated longevity of the patient must be carefully factored into the decision-making process. BEST PRACTICE ADVICE 8: The approach to endoscopic duodenal resection (ie, hot vs cold and conventional vs underwater endoscopic mucosal resection) should be individualized to reduce bleeding risk, based on lesion size, morphology, patient comorbidities, and endoscopist comfort level with specific techniques. Piecemeal cold snare resection for flat duodenal adenomas mitigates postprocedural bleeding risk and, for lesions <20 mm, is effective and carries a minimal risk of recurrence. In patients with comorbidities with flat nonbulky lesions measuring < 20 mm, cold snare resection can be considered. BEST PRACTICE ADVICE 9: Currently, duodenal adenomas >20 mm or with large Paris subtype Is components should be removed by conventional hot snare endoscopic mucosal resection. Thermal ablation of the post-endoscopic mucosal resection margin to mitigate the risk of recurrence to <2%-5% is safe and effective and should be considered. BEST PRACTICE ADVICE 10: Endoscopists performing duodenal polyp resection should be aware of the increased risk of postprocedural bleeding (compared with elsewhere in the gastrointestinal tract), which usually occurs in the first 48 hours after the procedure, with the risk proportional to the lesion size. For lesions >3 cm, bleeding risk is >25% and may be life-threatening and associated with hemodynamic compromise; however, after resuscitation, endoscopic hemostasis is generally effective. BEST PRACTICE ADVICE 11: Evaluation of the postpolypectomy/endoscopic mucosal resection defect is critical to identify concerns for postprocedural duodenal perforation, which, if unrecognized and left untreated, may be life-threatening and often mandates surgery. BEST PRACTICE ADVICE 12: Initial endoscopic surveillance for a completely resected duodenal adenoma should be undertaken at an interval of 6 months. Although usually diminutive, recurrence is often scarred and not amenable to conventional snare resection and may require avulsion techniques to achieve cure. BEST PRACTICE ADVICE 13: Nonampullary duodenal adenomas associated with familial adenomatous polyposis should be considered for endoscopic resection based on size (≥1 cm), morphologic characteristics, advanced histology (ie, high-grade dysplasia), and/or based on Spiegelman criteria.
参考来源
- Bourke MJ, Lo SK, Buerlein RCD, et al. AGA Clinical Practice Update on Nonampullary Duodenal Lesions: Expert Review. Gastroenterology. 2024. PMID: 39545885. doi:10.1053/j.gastro.2024.10.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。